Annuity payments can increase patient access to innovative cell and gene therapies under England’s net budget impact test
Background: Cell and gene therapies have the potential to provide therapeutic breakthroughs, but the high costs of researching, developing, manufacturing and delivering them translate into prices that may challenge healthcare budgets. Various measures exist that aim to address the affordability chal...
Main Authors: | Jesper Jørgensen, Panos Kefalas |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2017-01-01
|
Series: | Journal of Market Access & Health Policy |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/20016689.2017.1355203 |
Similar Items
-
Upgrading the SACT dataset and EBMT registry to enable outcomes-based reimbursement in oncology in England: a gap analysis and top-level cost estimate
by: Jesper Jørgensen, et al.
Published: (2019-01-01) -
The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson’s disease
by: Jesper Jørgensen, et al.
Published: (2018-01-01) -
Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations?
by: Virginia Ronco, et al.
Published: (2021-03-01) -
Advanced Therapy Medicinal Products for the Eye: Definitions and Regulatory Framework
by: Marina López-Paniagua, et al.
Published: (2021-03-01) -
Two Decades of Global Progress in Authorized Advanced Therapy Medicinal Products: An Emerging Revolution in Therapeutic Strategies
by: Roya Ramezankhani, et al.
Published: (2020-12-01)